- 100 free trades signup offer
- Easy-to-use platform
- Low fees
- Student and young investor discounts
Immix Biopharma is a biotechnology business based in the US. Immix Biopharma shares (IMMX) are listed on the NASDAQ and all prices are listed in US Dollars.
Its last market close was $2.17 – an increase of 6.37% over the previous week. Immix Biopharma employs 14 staff and has a market cap (total outstanding shares value) of 0.00.Our top picks for where to buy Immix Biopharma stock
- Access to international stock exchanges
- Low margin rates
- Powerful research tools
- 6% cash rebate plus $2,200 in trading perks
- Low transaction fees
- Easy-to-use app
How to buy Immix Biopharma stock
- Choose a stock trading platform. Compare investment platforms.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – IMMX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Immix Biopharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Note: The dollar amounts in the table below are in Canadian dollars.
Finder Score for stock trading platforms
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.
Immix Biopharma stock price (NASDAQ: IMMX)
Use our graph to track the performance of IMMX stocks over time.Immix Biopharma stocks at a glance
Latest market close | $2.17 |
---|---|
52-week range | $1.26 - $7.50 |
50-day moving average | $1.80 |
200-day moving average | $2.13 |
Wall St. target price | $7.00 |
PE ratio | N/A |
Dividend yield | N/A |
Earnings per share (TTM) | $-0.84 |
Is it a good time to buy Immix Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Immix Biopharma price performance over time
Historical closes compared with the close of $2.22 from 2024-12-19
1 week (2024-12-13) | 8.82% |
---|---|
1 month (2024-11-22) | 24.02% |
3 months (2024-09-20) | 23.33% |
6 months (2024-06-21) | 8.82% |
1 year (2023-12-22) | -69.12% |
---|---|
2 years (2022-12-22) | -8.64% |
3 years (2021-12-22) | 3.26 |
5 years (2019-12-18) | N/A |
Immix Biopharma financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -56.85% |
Return on equity TTM | -103.81% |
Profit margin | 0% |
Book value | $0.82 |
Market Capitalization | $57.8 million |
TTM: trailing 12 months
Immix Biopharma stock dividends
We're not expecting Immix Biopharma to pay a dividend over the next 12 months.
Immix Biopharma stock price volatility
Over the last 12 months, Immix Biopharma's stocks have ranged in value from as little as $1.26 up to $7.5. A popular way to gauge a stock's volatility is its "beta."
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immix Biopharma's is 0.104. This would suggest that Immix Biopharma's stocks are less volatile than average (for this exchange).
Immix Biopharma overview
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Frequently asked questions
What percentage of Immix Biopharma is owned by insiders or institutions?Currently 40.098% of Immix Biopharma stocks are held by insiders and 17.642% by institutions. How many people work for Immix Biopharma?
Latest data suggests 14 work at Immix Biopharma. When does the fiscal year end for Immix Biopharma?
Immix Biopharma's fiscal year ends in December. Where is Immix Biopharma based?
Immix Biopharma's address is: 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064 What is Immix Biopharma's ISIN number?
Immix Biopharma's international securities identification number is: US45258H1068
More on investing
How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…What are stocks?
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
Read more…More guides on Finder
-
How to buy Raytheon Technologies (RTX) stocks
Steps to owning and managing Raytheon Technologies Corp, with 24-hour and historical pricing before you buy.
-
How to buy Gildan Activewear (GIL) stocks
Steps to owning and managing Gildan Activewear Inc., with 24-hour and historical pricing before you buy.
-
Best renewable energy stocks
These are the best renewable energy stocks to buy now in Canada.
-
Best stocks to buy right now in Canada
Finder’s unique algorithm found the 20 best TSX stocks to buy right now.
-
How to buy IL Makiage stock in Canada when it goes public
Everything we know about the IL Makiage IPO plus information on how to buy in.
-
How to buy ByteDance stock in Canada when it goes public
Everything we know about the ByteDance IPO plus information on how to buy in.
-
How to buy Auvik Networks stock in Canada when it goes public
Everything we know about the Auvik Networks IPO plus information on how to buy in.
-
How to buy Universal Music Group (UMG) stock from Canada
If you live in Canada, you need a broker that provides access to foreign investments to buy Universal Music Group stock.
-
How to invest in the S&P 500 in Canada
Find out how to invest in the S&P 500 in Canada—one of the world’s most popular stock indices—to diversify your portfolio.
-
BMO InvestorLine review
Check out the pros and cons of BMO’s self-directed trading platform in our InvestorLine review.